Ionis Pharmaceuticals, Inc. IONS
44.50
0.69
1.57%
as of 25 Sep
- Market cap
- $7.4B
- P/E
- 0.0×
Follow IONS
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (105.50%) | (67.62%) | (70.80%) | (40.04%) |
+8 more TTM periods Free account |
|
| (18.90%) | (10.44%) | (11.69%) | (8.39%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(24.25%) | (13.84%) | (16.35%) | (14.89%) | |
Average Days of Receivables |
24.57 | 25.42 | 25.55 | 9.29 | |
Free Cash Flow per Share |
(3.43) | (5.93) | (2.04) | (1.94) | |
Free Cash Flow |
(567.50) | (977.73) | (325.67) | (309.48) | |
Capital Expenditures |
(71.07) | (67.10) | (57.08) | (62.47) | |
Piotroski F-Score |
2.00 | 3.00 | 3.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(12.91%) | (24.22%) | (5.43%) | (7.15%) | |
Accounts Receivable Turnover |
15.69 | 18.66 | 11.93 | 45.47 | |
Accounts Payable Turnover |
0.45 | 0.80 | 0.45 | 1.01 | |
Inventory Turnover |
0.54 | 2.04 | 1.41 | 0.61 | |
Average Days of Payables |
1,087.09 | 545.12 | 644.29 | 443.85 | |
Days of Inventory on Hand |
1,158.40 | 116.38 | 230.53 | 324.38 | |
Tax Rate |
0.01 | 0.01 | 0.00 | (0.01) | |
Research and Development Expense of Revenue |
105.79% | 87.42% | 97.02% | 91.16% | |
Selling, General and Administrative Expense of Revenue |
60.38% | 44.22% | 41.74% | 36.38% | |
Share Based Compensation of Revenue |
18.69% | 13.93% | 14.19% | 13.10% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 2.79 | 0.70 | 0.96 | |
Depreciation/Fixed assets |
0.09 | 0.07 | 0.05 | 0.00 | |
Capex/Depreciation |
(4.93) | (7.03) | (9.73) | 223.91 | |
Revenue per Share |
5.28 | 6.42 | 5.90 | 6.05 | |
Operating CF per Share |
(3.00) | (5.52) | (1.68) | (1.55) | |
Capex per Share |
(0.43) | (0.41) | (0.36) | (0.39) | |
Capex to Sales |
0.08 | 0.06 | 0.06 | 0.06 | |
Net Profit Margin |
(64.66%) | (30.90%) | (40.41%) | (26.51%) |
Columns are period end dates